WIM
UBX

Westside Investment Management’s Unity Biotechnology UBX Stock Holding History

Westside Investment Management’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10
Closed -$16 – 856
2023
Q1 		$16 Hold
10
– – ﹤0.01% 835
2022
Q4 		$0 Hold
10
– – ﹤0.01% 855
2022
Q3 		$0 Hold
10
– – ﹤0.01% 852
2022
Q2 		$0 Hold
10
– – ﹤0.01% 838
2022
Q1 		$0 Hold
10
– – ﹤0.01% 818
2021
Q4 		$0 Hold
10
– – ﹤0.01% 795
2021
Q3 		$0 Hold
10
– – ﹤0.01% 767
2021
Q2 		$0 Hold
10
– – ﹤0.01% 760
2021
Q1 		$0 Hold
10
– – ﹤0.01% 751
2020
Q4 		$0 Hold
10
– – ﹤0.01% 680
2020
Q3 		$1 Hold
10
– – ﹤0.01% 660
2020
Q2 		$1 Sell
10
-10
-50% -$742 ﹤0.01% 647
2020
Q1 		$1 Buy
+20
New +$1.26K ﹤0.01% 660
2019
Q2 		$1 Buy
+20
New +$1.7K ﹤0.01% 638

Other funds holding UBX

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
FFVM
Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return

Westside Investment Management's UBX Position: Q2 2023 in Review

Westside Investment Management sold out of Unity Biotechnology (UBX) in Q2 2023, closing a stake of 10 shares — an estimated $16 sold.

Westside Investment Management first reported a position in UBX in Q2 2019 and held it in 14 quarters. The position peaked at $16 in Q1 2023. 40 funds tracked by Wall St. Rank hold UBX as of Q2 2023.

  • Westside Investment Management reported no remaining Unity Biotechnology position as of Q2 2023 after selling out during the quarter.
  • Westside Investment Management sold 10 Unity Biotechnology shares in Q2 2023, an estimated $16.
  • Westside Investment Management first reported a position in Unity Biotechnology in Q2 2019 and held it in 14 quarters.
  • Westside Investment Management's Unity Biotechnology position peaked at $16 in Q1 2023.
  • 40 funds tracked by Wall St. Rank held Unity Biotechnology as of Q2 2023.

Based on Westside Investment Management's 13F filing for Q2 2023, filed 14 Jul 2023.